CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 94 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,307 | -100.0% | 395 | -96.4% | 0.00% | – |
| Q3 2022 | $74,115,000 | +15087.5% | 11,062 | +9436.2% | 0.00% | – |
| Q2 2022 | $488,000 | +34.1% | 116 | +7.4% | 0.00% | – |
| Q1 2022 | $364,000 | -99.5% | 108 | -99.6% | 0.00% | – |
| Q4 2021 | $77,282,000 | +21792.9% | 24,534 | +22616.7% | 0.00% | – |
| Q3 2021 | $353,000 | -13.7% | 108 | +11.3% | 0.00% | – |
| Q2 2021 | $409,000 | -99.3% | 97 | -99.1% | 0.00% | – |
| Q1 2021 | $54,875,000 | -24.3% | 10,997 | +91.7% | 0.00% | – |
| Q4 2020 | $72,528,000 | +9.6% | 5,738 | -14.9% | 0.00% | – |
| Q3 2020 | $66,187,000 | +438.6% | 6,740 | +445.7% | 0.00% | – |
| Q2 2020 | $12,288,000 | -82.9% | 1,235 | -84.8% | 0.00% | – |
| Q1 2020 | $71,745,000 | +49.2% | 8,116 | +55.7% | 0.00% | – |
| Q4 2019 | $48,081,000 | +139.0% | 5,212 | +52.3% | 0.00% | – |
| Q3 2019 | $20,121,000 | -29.3% | 3,422 | +44.2% | 0.00% | – |
| Q2 2019 | $28,476,000 | -46.8% | 2,373 | -46.4% | 0.00% | – |
| Q1 2019 | $53,482,000 | +60675.0% | 4,431 | +63200.0% | 0.00% | – |
| Q4 2018 | $88,000 | -99.1% | 7 | -99.0% | 0.00% | – |
| Q3 2018 | $10,329,000 | -11.8% | 696 | 0.0% | 0.00% | – |
| Q2 2018 | $11,714,000 | -86.4% | 696 | -81.5% | 0.00% | – |
| Q1 2018 | $86,127,000 | -10.6% | 3,761 | +1.0% | 0.00% | – |
| Q4 2017 | $96,288,000 | +288.8% | 3,722 | +121.7% | 0.00% | – |
| Q3 2017 | $24,765,000 | -1.9% | 1,679 | -7.2% | 0.00% | – |
| Q2 2017 | $25,250,000 | +4524.5% | 1,810 | +5556.2% | 0.00% | – |
| Q1 2017 | $546,000 | -81.6% | 32 | -88.9% | 0.00% | – |
| Q4 2016 | $2,974,000 | -75.9% | 289 | -76.4% | 0.00% | – |
| Q3 2016 | $12,354,000 | +70.8% | 1,222 | +89.8% | 0.00% | – |
| Q2 2016 | $7,232,000 | +615.3% | 644 | +770.3% | 0.00% | – |
| Q1 2016 | $1,011,000 | -98.1% | 74 | -97.4% | 0.00% | – |
| Q4 2015 | $54,140,000 | -9.3% | 2,854 | -10.3% | 0.00% | – |
| Q3 2015 | $59,707,000 | +213.3% | 3,181 | +148.5% | 0.00% | – |
| Q2 2015 | $19,059,000 | +2634.4% | 1,280 | +1755.1% | 0.00% | – |
| Q2 2014 | $697,000 | – | 69 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |